首页> 外文期刊>Cellular immunology >B7-H4.Ig inhibits the development of Type 1 diabetes by regulating Th17 cells in NOD mice
【24h】

B7-H4.Ig inhibits the development of Type 1 diabetes by regulating Th17 cells in NOD mice

机译:B7-H4.Ig通过调节NOD小鼠Th17细胞来抑制1型糖尿病的发展

获取原文
获取原文并翻译 | 示例
       

摘要

Type 1 diabetes (T1D) is an autoimmune disease characterized by immunological destruction of insulin-producing pancreatic β-cells and subsequent hyperglycemia. The non-obese diabetic (NOD) mouse strain spontaneously develops a disease similar to human T1D and is commonly used as an animal model for studying this disease. We have previously shown that the administration of B7-H4-immunoglobulin fusion protein (B7-H4.Ig), a newly identified T-cell co-inhibitory signaling molecule, blocks the onset of diabetes in NOD mice. However, the mechanism(s) by which B7-H4 protects NOD mice from T1D is not fully understood. IL-17 is a pro-inflammatory cytokine, produced by Th17 cells, that activates T cells and other immune cells to produce a variety of cytokines and chemokines. Increasing evidence has shown that therapeutic agents targeting the IL-17 molecule or directly inhibiting IL-17-producing cells regulate autoimmune diabetes in NOD mice, suggesting that IL-17 is involved in the pathogenesis of this disease. In this study, we investigate whether B7-H4.Ig treatment inhibits the generation of Th17 cells which subsequently decreases IL-17 production and prevents the onset of T1D in NOD mice. Pre-diabetic female NOD mice were injected intraperitoneally with control mouse IgG or B7-H4.Ig starting at 4. weeks of age for 12. weeks. Our data showed that the frequency of Th17 cells in B7-H4.Ig-treated mice was significantly decreased. In addition, our data showed that B7-H4.Ig-treated mice had decreased levels of pro-inflammatory cytokines and Th17-associated cytokines, and an increased level of the potent Th17 inhibitor IFN-γ. To further investigate the effect of B7-H4.Ig on differentiation of Th17 cells, we co-cultured splenocytes with Th17-polarizing cytokines in the absence or presence of B7-H4.Ig. Our results indicated that splenocytes, under the Th17 driving conditions in the presence of B7-H4.Ig, had significantly decreased the numbers of Th17 cells compared to cells co-cultured in the absence of B7-H4.Ig. Together, this study suggests that blocking the generation of Th17 cells with the administration of B7-H4.Ig effectively inhibits the development of T1D in NOD mice.
机译:1型糖尿病(T1D)是一种自身免疫性疾病,其特征是产生胰岛素的胰岛β细胞发生免疫破坏和随后的高血糖症。非肥胖糖尿病(NOD)小鼠品系会自发发展出一种类似于人T1D的疾病,通常被用作研究该疾病的动物模型。先前我们已经表明,新鉴定的T细胞共抑制信号分子B7-H4-免疫球蛋白融合蛋白(B7-H4.Ig)的使用可阻止NOD小鼠中糖尿病的发作。但是,尚不完全了解B7-H4保护NOD小鼠免受T1D侵害的机制。 IL-17是由Th17细胞产生的促炎性细胞因子,可激活T细胞和其他免疫细胞以产生多种细胞因子和趋化因子。越来越多的证据表明,靶向IL-17分子或直接抑制IL-17产生细胞的治疗剂可调节NOD小鼠的自身免疫性糖尿病,提示IL-17参与了该病的发病机理。在这项研究中,我们调查了B7-H4.Ig处理是否抑制Th17细胞的生成,从而降低了IL-17的产生并阻止了NOD小鼠中T1D的发作。从4周龄开始,对糖尿病前雌性NOD小鼠腹膜内注射对照小鼠IgG或B7-H4.Ig,持续12周。我们的数据显示,B7-H4.Ig处理的小鼠中Th17细胞的频率显着降低。此外,我们的数据显示,B7-H4.Ig治疗的小鼠的促炎细胞因子和与Th17相关的细胞因子水平降低,而有效的Th17抑制剂IFN-γ水平升高。为了进一步研究B7-H4.Ig对Th17细胞分化的影响,我们在不存在或存在B7-H4.Ig的情况下,将脾细胞与Th17极化细胞因子共培养。我们的结果表明,与在不存在B7-H4.Ig的情况下共培养的细胞相比,在Th17驱动条件下存在B7-H4.Ig的脾细胞已显着减少了Th17细胞的数量。总之,这项研究表明,通过施用B7-H4.Ig来阻止Th17细胞的生成可有效抑制NOD小鼠中T1D的发育。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号